DAOHE GLOBAL (00915) issues profit warning, expecting annual profit not exceeding approximately $100,000, a significant decrease compared to the previous year.
Tao and Global (00915) has announced that the group expects to record a comprehensive annual surplus of no more than approximately $100,000 for the year ending December 31, 2025, compared to a comprehensive annual surplus of approximately $2.7 million for the year ending December 31, 2024. The surplus has significantly decreased.
DAOHE GLOBAL (00915) announces that the group is expected to record a comprehensive annual profit of not more than approximately $100,000 for the year ending December 31, 2025, compared to the comprehensive annual profit of approximately $2.7 million for the year ending December 31, 2024. The profit has decreased significantly.
The board of directors believes that the main reasons for the expected decrease in comprehensive profit for the year ending December 31, 2025, are as follows: 1. The ongoing international trade tensions have intensified the challenges and uncertainties in the business environment, impacting customer consumption intentions. Customers are adopting more conservative purchasing strategies, leading to a decrease in revenue for the trade and supply chain management services division by approximately 21% compared to last year; and 2. Influenced by market saturation and weak consumer spending, the growth of the trendy toy business has slowed down, resulting in a year-on-year decrease in revenue for the cultural and entertainment division by approximately 23%.
Related Articles

Shenyang Public Utility Development Co., Ltd. (00747) issued a profit warning, expecting pre-tax loss to increase by approximately 60% to 70% compared to 2025.

Yunji (02670) proposes to appoint Wang Kegui as a candidate for non-executive director.

"Strong partnership! AB&B BIO-TECH-B (02627) joins hands with Walvax Biotechnology to start the new journey of exporting third-generation flu vaccines."
Shenyang Public Utility Development Co., Ltd. (00747) issued a profit warning, expecting pre-tax loss to increase by approximately 60% to 70% compared to 2025.

Yunji (02670) proposes to appoint Wang Kegui as a candidate for non-executive director.

"Strong partnership! AB&B BIO-TECH-B (02627) joins hands with Walvax Biotechnology to start the new journey of exporting third-generation flu vaccines."

RECOMMEND

“A+H” Team Continues To Expand Hard Technology Firms Accelerate Global Deployment
11/03/2026

Anti‑Stagflation Theme Guides Hong Kong Allocation Institutions Identify Power And Energy Assets As Short‑Term Core
11/03/2026

U.S. Equities Enter “Always‑On” Trading Era Nasdaq Advances Stock Tokenization Framework
11/03/2026


